Selank and Semax as 'brain upgrades': what the science says

What's this video probably claiming?

Based on the caption framing and hashtag stack, this video almost certainly positions Selank and Semax as a synergistic nootropic combination, the kind of thing biohacking communities call a "stack." The creator is likely describing cognitive benefits, reduced anxiety, improved focus, or mood stabilization, possibly drawing on anecdotal experience. The "brain upgrade you didn't know you needed" framing is a classic social media hook that implies these peptides are both safe and obviously effective, which is doing a lot of work for two compounds that have almost no clinical data in Western populations. The video probably doesn't mention that both are research-stage peptides with no FDA approval, no standardized dosing, and no long-term safety data in humans. It also likely doesn't mention that sourcing these compounds outside a regulated telehealth context means quality, purity, and concentration are essentially unknown. That context matters enormously and is almost always missing from the 60-second format.

What does the science actually show?

Selank is a synthetic heptapeptide derived from tuftsin, developed in Russia by the Institute of Molecular Genetics. Russian clinical studies, including work by Seredenin and colleagues published in Eksperimental'naya i Klinicheskaya Farmakologiya (2000), reported anxiolytic effects at intranasal doses around 400 mcg per day in patients with generalized anxiety disorder, with effects comparable to phenazepam but without sedation. Semax is a synthetic ACTH analog also developed in Russia, with studies such as Gusev et al. (1997) in Cerebrovascular Diseases reporting improved outcomes in ischemic stroke patients at 0.1 mg/kg/day doses. Both compounds appear to influence BDNF expression and serotonin/dopamine systems in animal models. However, virtually all human trial data originates from Russian-language literature, conducted under regulatory frameworks that differ substantially from FDA or EMA standards. No large-scale randomized controlled trials exist in peer-reviewed Western journals. That's not a minor footnote. That's the core problem with treating this evidence as settled science.

Where does the social media noise diverge from clinical reality?

The biohacking community treats the Russian research as essentially equivalent to FDA-reviewed trial data. It isn't. The studies that do exist are small, often unblinded, and published in journals with limited independent replication. When TikTok creators stack Selank with Semax and describe the combination as a "brain upgrade," they're extrapolating far beyond what any published data supports for healthy individuals seeking cognitive enhancement. The existing human trials studied clinical populations, specifically people with anxiety disorders or stroke, not healthy adults trying to optimize focus. There's also a sourcing problem that almost never gets mentioned. Peptides sold through gray-market vendors vary dramatically in purity. A 2020 analysis by Abbate et al. in the Journal of Pharmaceutical and Biomedical Analysis found significant contamination and mislabeling in peptide products sold online. The "stack" framing also implies the combination has been studied, which it hasn't. Claiming synergy between two inadequately studied compounds is speculation dressed up as protocol.

What should you actually know?

If you're genuinely interested in Selank or Semax, the honest starting point is that these are research-stage peptides with a plausible mechanistic basis and some limited human data, but no regulatory approval outside Russia and no established safety profile for long-term use in healthy adults. The anxiety-reduction effects of Selank are the most credible piece of the evidence base, with multiple Russian studies showing effects over 14-day periods. Semax's cognitive effects in healthy subjects remain largely anecdotal. Neither compound should be self-administered based on TikTok protocols. Anyone considering these through a telehealth provider should expect a thorough intake, documented baseline assessment, and ongoing monitoring. The absence of serious adverse event reporting in the literature is not the same as a confirmed safety record, and the intranasal delivery route, while convenient, has its own absorption variability. Short version: interesting compounds, genuinely understudied, and radically overhyped in the biohacking space relative to what the data actually supports.